36,117 Shares of Revvity Inc. $RVTY Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Revvity Inc. (NYSE:RVTY) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 36,117 shares of the company’s stock, valued at approximately $5,522,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. EdgePoint Investment Group Inc. lifted its stake in shares of Revvity by 3.1% during the first quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock valued at $771,044,000 after buying an additional 265,204 shares during the period. Jupiter Topco LLC purchased a new stake in Revvity in the 2nd quarter worth approximately $961,017,000. Janus Henderson Group PLC grew its stake in Revvity by 2.3% in the 1st quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company’s stock worth $731,386,000 after acquiring an additional 186,956 shares during the period. BlackRock Inc. purchased a new stake in Revvity in the 2nd quarter worth approximately $852,070,000. Finally, State Street Corp raised its holdings in Revvity by 0.8% in the 2nd quarter. State Street Corp now owns 4,342,739 shares of the company’s stock valued at $483,173,000 after acquiring an additional 32,426 shares during the last quarter. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on RVTY shares. KeyCorp increased their price target on Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a research note on Friday, September 4th. TD Cowen raised their price objective on Revvity from $175.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday. Bank of America reaffirmed a “neutral” rating on shares of Revvity in a research report on Wednesday. UBS Group assumed coverage on Revvity in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 target price for the company. Finally, Barclays increased their target price on Revvity from $160.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Six research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $133.86.

Revvity Price Performance

RVTY opened at $151.12 on Friday. The company’s 50 day simple moving average is $147.08 and its 200 day simple moving average is $113.03. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 2.65. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $171.74. The stock has a market capitalization of $16.86 billion, a PE ratio of 28.73, a P/E/G ratio of 2.80 and a beta of 1.08.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.30 by $0.08. Revvity had a net margin of 8.61% and a return on equity of 8.64%. The firm had revenue of $728.90 million during the quarter, compared to analyst estimates of $694.73 million. During the same quarter in the prior year, the business posted $1.18 earnings per share. Revvity’s revenue for the quarter was up 4.3% compared to the same quarter last year. As a group, sell-side analysts expect that Revvity Inc. will post 5.42 EPS for the current year.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 12th. Shareholders of record on Friday, January 22nd will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, January 22nd. Revvity’s dividend payout ratio (DPR) is 13.33%.

Key Stories Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported adjusted earnings of $1.38 per share, beating the $1.30 consensus, while revenue of $728.9 million also exceeded expectations and grew 4.3% year over year. Coverage highlighted AI-related demand and operational execution as growth drivers. RVTY Q3 deep dive: AI demand and operational execution drive broad-based growth
• Positive Sentiment: CFRA upgraded the shares from Hold to Buy. TD Cowen also maintained a Buy rating and raised its price target to $185 from $175, while Barclays lifted its target to $175 from $160. TD Cowen recommendations
• Neutral Sentiment: JPMorgan raised its price target to $160 from $155 but kept a Neutral rating. RBC raised its target sharply, to $172 from $135, while retaining Sector Perform. These target increases suggest improved expectations, but the ratings signal caution from some firms. JPMorgan recommendations
• Negative Sentiment: Despite the earnings beat, coverage raised the question of whether the stock is now too expensive. Its elevated valuation could limit upside or make the shares vulnerable to profit-taking after reaching a one-year high. Revvity reaffirms its dividend: Is the stock now too pricey?

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 7,330 shares of the company’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider directly owned 6,635 shares in the company, valued at $934,738.80. This represents a 52.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the transaction, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 9,045 shares of company stock valued at $1,281,439 over the last three months. Corporate insiders own 0.85% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.